个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey.

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Hong Zhao[1,2] ; Aiping Zhou[3] ; Jianguo Zhou[1] ; Xinyu Bi[1,2] ; Shida Yan[1] ; Jing Jin[4] ; Wenqiang Wei[5] ; Muxing Li[6] ; Caifeng Gong[3] ; Qichen Chen[1] ; Zhiwen Luo[1] ; Ning Li[4] ; Rui Mao[1] ; Xiao Chen[1] ; Bo Chen[4] ; Rongshou Zheng[5] ; Jianjun Zhao[1] ; Yue Han[7] ; Zhiyu Li[1] ; Xu Che[8,9] ; Yuan Tang[4] ; Yongkun Sun[3] ; Zhen Huang[1] ; Yefan Zhang[1] ; Xiaoying Wang[10] ; Yubao Zhang[11] ; Zhenhui Lu[12] ; Xiaowei Dang[13] ; Tianqiang Song[14] ; Chang Liu[15] ; Ping Yue[16] ; Dong Yan[17] ; Aimin Yue[18] ; Rui Zhang[19] ; Suxia Luo[20] ; Jing Tan[21] ; Xuewen Zhang[22] ; Xueli Bai[23] ; Xuejun Zhang[24] ; Mingyan He[25] ; Yujun Xie[26] ; Wenling Wang[27] ; Po Yang[28] ; Yijun Yang[29] ; Yamin Zhang[30] ; Qingdong Li[31] ; Tao Peng[32] ; Zusen Wang[33] ; Yajin Chen[34] ; Changzhen Shang[34] ; Yingjian Liang[35] ; Bixiang Zhang[36] ; Feng Zhang[37] ; Liming Wang[38] ; Duo Li[39] ; Bin Liu[40] ; Xiaofeng Zhu[41] ; Qinggang Hu[42] ; Minshan Chen[43] ; Dianrong Xiu[6] ; Feng Xia[44] ; Yanqiao Zhang[45] ; Yong Zeng[46] ; Yilei Mao[47] ; Xun Li[16] ; Yi Ba[48] ; Tingbo Liang[23] ; Feng Shen[49] ; Lianxin Liu[50] ; Xiujun Cai[51] ; Jian Zhou[10] ; Jianqiang Cai[1,2,*1] ;
机构： [1]Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, [2]KeyLaboratory of Gene Editing Screening and R&D of Digestive System Tumor Drugs, [3]Department of Medical Oncology, [4]Department ofRadiation Oncology, [5]Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, [6]Department of General Surgery, Peking UniversityThird Hospital, [7]Department of Interventional Therapy, [8]Department of Pancreatic and Gastric Surgery, National Cancer Center/NationalClinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing, [9]Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, [10]Department of Liver Surgery & Liver Transplant Center, Zhongshan Hospital, Fudan University, Shanghai, [11]Department of Hepatobiliaryand Pancreatic Surgery, Harbin Medical University Cancer Hospital, Harbin, [12]Departments of Hepatobiliary Surgery, GeneralHospital of Ningxia Medical University, Yinchuan, [13]Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital ofZhengzhou University, Zhengzhou, [14]Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute & Hospital,Tianjin, [15]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, [16]Department of GeneralSurgery, The First Hospital of Lanzhou University, Lanzhou, [17]Department of Hepatopancreatobiliary Surgery, The Affiliated TumorHospital of Xinjiang Medical University, Urumqi, [18]Department of Surgical Oncology, Xinxiang Central Hospital, Xinxiang, [19]Departmentof Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, [20]Henan CancerHospital, Zhengzhou, [21]Yan’an Affiliated Hospital of Kunming Medical University, Kunming, [22]Department of Hepatobiliary andPancreatic Surgery, The Second Hospital of Jilin University, Changchun, [23]Department of Hepatobiliary and Pancreatic Surgery, TheFirst Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang Clinical Research Cneter of Hepatobiliary and PancreaticDiseases, Hangzhou, [24]Department of Intervention, Inner Mongolia People’s Hospital, Hohhot, [25]Department of the Third AbdominalSurgery, Gansu Provincial Cancer Hospital, Lanzhou, [26]Department of Intervention Ultrasound, Ningxia People’s Hospital, Yinchuan, [27]Department of Oncology, The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, [28]Department of Interventional &Vascular Therapy, The Fourth Hospital of Harbin Medical University, Harbin, [29]Department of Hepatobiliary Surgery, Haikou MunicipalHospital, Haikou, [30]Department of Hepatobiliary Surgery, Tianjin First Center Hospital, Tianjin, [31]Vascular and Interventional Department,Chongqing University Cancer Hospital, Chongqing, [32]Department of Hepatobiliary Surgery, The First Affiliated Hospital ofGuangxi Medical University, Nanning, [33]Department of Hepatobiliary Surgery, The Affiliated Hospital of Qingdao University, Qingdao, [34]Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, [35]Department ofGeneral Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, [36]Hepatic Surgery Center, Tongji Hospital, TongjiMedical College of Huazhong University of Science and Technology, [37]Department of Hepatobiliary and Pancreatic Surgery, HubeiCancer Hospital, Wuhan, [38]Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Dalian Medical University,Dalian, [39]Department of Hepatopancreatobiliary Surgery, Hainan Cancer Hospital, Haikou, [40]Department of Hepatobiliary andPancreatic Surgery, The First Affiliated Hospital of Kunming Medical University, Kumming, [41]Department of Transplantation, The FirstAffiliated Hospital, Sun Yat-sen University, Guangzhou, [42]Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan, [43]Department of Hepatobiliary Surgery, Sun Yat-sen University CancerCenter, Guangzhou, [44]Institute of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing, [45]Department ofGastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, [46]Department of Liver Surgery, West ChinaHospital, Sichuan University, Chengdu, [47]Department of Liver Surgery, Peking Union Medical College Hospital, Peking Union MedicalCollege, Beijing, [48]Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’sClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, [49]Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, [50]Department of Hepatobiliary Surgery, The First Affiliated Hospital of University of Science and Technology of China, [51]Sir RunRun Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
出处：
DOI： 10.1016/j.hpb.2021.07.002
ISSN：

摘要：
This study aimed to investigate the work status of clinicians in China and their management strategy alteration for patients with hepatocellular carcinoma (HCC) during the COVID-19 pandemic.A nationwide online questionnaire survey was conducted in 42 class-A tertiary hospitals across China. Experienced clinicians of HCC-related specialties responded with their work status and management suggestions for HCC patients during the pandemic.716 doctors responded effectively with a response rate of 60.1%, and 664 were included in the final analysis. Overall, 51.4% (341/664) of clinicians reported more than a 60% reduction of the regular workload and surgeons declared the highest proportion of workload reduction. 92.5% (614/664) of the respondents have been using online medical consultation to substitute for the "face-to-face" visits. Adaptive adjustment for the treatment strategy for HCC was made, including the recommendations of noninvasive and minimally invasive treatments such as transcatheter arterial chemoembolization for early and intermediate stage. Targeted therapy has been the mainstay for advanced stage and also as a bridge therapy for resectable HCC.During the COVID-19 pandemic, online medical consultation is recommended to avoid social contact. Targeted therapy as a bridge therapy is recommended for resectable HCC considering the possibility of delayed surgery.Copyright © 2021. Published by Elsevier Ltd.

基金：
State Key Project on Infection Diseases of China (2017ZX10201021-007-003), CAMS Innovation Fund for Medical Sciences (CIFMS) (2017-12M-4-002), and the Key Laboratory Project of Chinese Academy of Medical Sciences (2019PT310026).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 3 区 医学
小类 | 3 区 胃肠肝病学 3 区 外科
最新[2023]版：
大类 | 3 区 医学
小类 | 3 区 外科 4 区 胃肠肝病学
第一作者：
第一作者机构： [1]Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, [2]KeyLaboratory of Gene Editing Screening and R&D of Digestive System Tumor Drugs,
共同第一作者：
通讯作者：
通讯机构： [1]Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, [2]KeyLaboratory of Gene Editing Screening and R&D of Digestive System Tumor Drugs, [*1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China.
推荐引用方式(GB/T 7714)：
Hong Zhao,Aiping Zhou,Jianguo Zhou,et al.Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey.[J].HPB : The Official Journal Of The International Hepato Pancreato Biliary Association.2021,doi:10.1016/j.hpb.2021.07.002.
APA：
Hong Zhao,Aiping Zhou,Jianguo Zhou,Xinyu Bi,Shida Yan...&Jianqiang Cai.(2021).Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey..HPB : The Official Journal Of The International Hepato Pancreato Biliary Association,,
MLA：
Hong Zhao,et al."Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey.".HPB : The Official Journal Of The International Hepato Pancreato Biliary Association .(2021)

资源点击量：46667 今日访问量：3 总访问量：3332 更新日期：2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号